2-(4-硝基苯基)-1H-咪唑并(4,5-b)吡啶 | 63581-48-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 中文名称: 2-(4-硝基苯基)-1H-咪唑并(4,5-b)吡啶
• 英文名称: 2-p-nitrophenyl-3H-imidazo<4,5-b>pyridine
• 英文别名: 2-(4-Nitrophenyl)-1H-imidazo(4,5-b)pyridine；2-(4-nitrophenyl)-1H-imidazo[4,5-b]pyridine
• CAS: 63581-48-6
• 化学式: C₁₂H₈N₄O₂
• 分子量: 240.221
• InChiKey: SNEPVAQSJPTXCK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  18
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  87.4
• 氢给体数：
  1
• 氢受体数：
  4

安全信息

• 海关编码：
  2933990090

反应信息

• 作为反应物：
  描述：

  2-(三甲基硅烷基)乙氧甲基氯 、 2-(4-硝基苯基)-1H-咪唑并(4,5-b)吡啶 在 sodium hydride 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 生成 、
  参考文献：
  名称：

  Discovery of oxazolo[4,5-b]pyridines and related heterocyclic analogs as novel SIRT1 activators

  摘要：

  SIRT1 is an NAD(+)-dependent protein deacetylase that appears to produce beneficial effects on metabolic parameters such as glucose and insulin homeostasis. Activation of SIRT1 by resveratrol ( 1) has been shown to modulate insulin resistance, increase mitochondrial content and prolong survival in lower organisms and in mice on a high fat diet. Herein, we describe the identification and SAR of a series of oxazolo[4,5-b]pyridines as novel small molecule activators of SIRT1 which are structurally unrelated to and more potent than resveratrol. (C) 2009 Published by Elsevier Ltd.

  DOI：

  10.1016/j.bmcl.2008.11.106
• 作为产物：
  描述：

  N³-(4-nitrobenzylidene)pyridine-2,3-diamine 在 lead(IV) acetate 、 溶剂黄146 作用下， 反应 0.5h， 以98%的产率得到2-(4-硝基苯基)-1H-咪唑并(4,5-b)吡啶
  参考文献：
  名称：

  Dubey; Kumar, R. Vinod; Kulkarni, Subhash M., Indian Journal of Chemistry - Section B Organic and Medicinal Chemistry, 2004, vol. 43, # 5, p. 952 - 956

  摘要：

  DOI：

文献信息

• Synthesis of imidazo[4,5-<i>b</i>]- and [4,5-<i>c</i>]pyridines
  作者：Richard W. Middleton、D. George Wibberley

  DOI：10.1002/jhet.5570170824

  日期：1980.12

  2-Arylimidazo[4,5-b]- and [4,5-c]pyridines have been prepared by treatment of the appropriate 2,3- or 3,4-diaminopyridine with an aromatic carboxylic acid in the presence of polyphosphoric acid. Other derivatives have been prepared by similar cyclisation of diaminopyridines using triethyl orthoformate, urea, thiophosgene and thiourea and the properties of some N-oxides have been investigated. A number

  通过在多磷酸存在下用芳族羧酸处理适当的2,3-或3,4-二氨基吡啶，可以制备2-Arylimidazoazo [4,5- b ]-和[4,5- c ]吡啶。使用原甲酸三乙酯，尿素，硫光气和硫脲，通过二氨基吡啶的类似环化反应，已经制备了其他衍生物，并且已经研究了一些N-氧化物的性质。已经筛选了许多芳基咪唑并吡啶的致突变性。
• Eco-friendly and facile synthesis of 2-substituted-1H-imidazo[4,5-b]pyridine in aqueous medium by air oxidation
  作者：Rajesh P. Kale、Mohammad U. Shaikh、Ganesh R. Jadhav、Charansingh H. Gill

  DOI：10.1016/j.tetlet.2008.12.104

  日期：2009.4

  a new environmentally-benign, convenient, and facile methodology for the synthesis of 2-substituted-1H-imidazo[4,5-b]pyridine. The reaction of 2,3-diaminopyridine with substituted aryl aldehydes in water under thermal conditions without the use of any oxidative reagent has been studied. The reaction has yielded 1H-imidazo[4,5-b]pyridine derivatives by an air oxidative cyclocondensation reaction in

  我们报告了一种新的环境友好，方便，简便的方法合成2-取代-1 H-咪唑并[4,5- b ]吡啶。研究了2,3-二氨基吡啶与取代的芳基醛在水中在热条件下不使用任何氧化剂的反应。反应产生1 H-咪唑并[4,5- b吡啶衍生物通过空气氧化环缩合反应一步一步即可获得极佳的收率。此外，合成了一系列化合物，并通过熔点，EI-MS，NMR和IR工具对其进行了表征。为了比较，参考样品通过报道的方法制备。从经济和环境的角度来看，利用水性介质，容易的反应条件，分离和纯化使这种操作非常有趣。
• Sirtuin modulating compounds
  申请人：Nunes J. Joseph

  公开号：US20070037809A1

  公开（公告）日：2007-02-15

  Provided herein are novel sirtuin-modulating compounds and methods of use thereof. The sirtuin-modulating compounds may be used for increasing the lifespan of a cell, and treating and/or preventing a wide variety of diseases and disorders including, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting disorders, inflammation, cancer, and/or flushing as well as diseases or disorders that would benfit from increased mitochondrial activity. Also provided are compositions comprising a sirtuin-modulating compound in combination with another therapeutic agent.

  本文提供了新型的sirtuin调节化合物及其使用方法。这些sirtuin调节化合物可用于增加细胞寿命，并治疗和/或预防各种疾病和疾病，包括与衰老或应激有关的疾病或疾病，糖尿病，肥胖症，神经退行性疾病，心血管疾病，血液凝块性疾病，炎症，癌症和/或红斑病，以及需要增加线粒体活性的疾病或疾病。还提供了包含sirtuin调节化合物和另一种治疗剂的组合物。
• SIRTUIN MODULATING COMPOUNDS
  申请人：Nunes Joseph J.

  公开号：US20120197013A1

  公开（公告）日：2012-08-02

  Provided herein are novel sirtuin-modulating compounds and methods of use thereof. The sirtuin-modulating compounds may be used for increasing the lifespan of a cell, and treating and/or preventing a wide variety of diseases and disorders including, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting disorders, inflammation, cancer, and/or flushing as well as diseases or disorders that would benefit from increased mitochondrial activity. Also provided are compositions comprising a sirtuin-modulating compound in combination with another therapeutic agent.

  本文提供了一种新颖的调节沉默信息调节因子（sirtuin）的化合物及其使用方法。这些调节sirtuin的化合物可用于延长细胞寿命，并用于治疗和/或预防多种疾病和障碍，包括与衰老或应激有关的疾病或障碍、糖尿病、肥胖症、神经退行性疾病、心血管疾病、血液凝结障碍、炎症、癌症和/或潮红，以及需要增加线粒体活性的疾病或障碍。还提供了包含sirtuin调节化合物与另一种治疗药物组合的组合物。
• Imidazo[2,1-b]thiazole derivatives as sirtuin modulators
  申请人：Sirtris Pharmaceuticals, Inc.

  公开号：EP2388263A1

  公开（公告）日：2011-11-23

  Provided herein are novel sirtuin-modulating compounds and methods of use thereof. The sirtuin-modulating compounds may be used for increasing the lifespan of a cell, and treating and/or preventing a wide variety of diseases and disorders including, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting disorders, inflammation, cancer, and/or flushing as well as diseases or disorders that would benfit from increased mitochondrial activity. Also provided are compositions comprising a sirtuin-modulating compound in combination with another therapeutic agent.

  本文提供了新型sirtuin调节化合物及其使用方法。sirtuin调节化合物可用于延长细胞寿命，治疗和/或预防多种疾病和失调，包括与衰老或压力、糖尿病、肥胖症、神经退行性疾病、心血管疾病、凝血障碍、炎症、癌症和/或潮红有关的疾病或失调，以及可从线粒体活性增强中获益的疾病或失调。此外，还提供了由sirtuin调节化合物与另一种治疗剂组合而成的组合物。